Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma reported its Q1 2026 financial results and highlighted progress in its clinical-stage oncology pipeline, including ongoing global Phase 1/2 trials of CR-001, CR-002, and CR-003 targeting multiple solid tumors. The company announced upcoming clinical data readouts starting in Q1 2027 and collaboration with Kelun-Biotech to expand …